Our contract negotiation skills need to go beyond getting a great deal in the short term. As a failed partnership on Covid-19 vaccine production illustrates, strong safeguards and oversight are needed to ensure long-term success.
BY KATIE SHONK — ON MARCH 11TH, 2025 / DEALMAKING
Business negotiators tend to focus on getting to the finish line, which is typically defined as a signed contract. The contract negotiation skills we need to get there—such as building trust, brainstorming issues, and negotiating a great price—are pivotal, yet we often overlook the importance of setting up our agreement for success during the implementation stage. A private-public partnership intended to speed up the production of vaccines in response to virus outbreaks shows how badly things can go wrong.
A New Partner Fails the Test
After the 2009 H1N1 influenza outbreak claimed an estimated 12,000 lives in the United States, the Obama administration set a goal of bringing vaccines to market more quickly in response to future virus outbreaks. The initiative included forming partnerships with several vaccine producers, according to the New York Times.
In the years that followed, the U.S. Department of Health and Human Services paid Maryland biotech firm Emergent to have a factory ready to produce up to 50 million doses of vaccine within four months of the start of a flu pandemic. To test whether Emergent would be up to the job, the government assigned the firm to develop a flu vaccine with another company and have it approved in about eight years, the Times reports.
Unfortunately, in the years that followed, the U.S. government office overseeing Emergent’s work, the Biomedical Advanced Research and Development Authority, “acted more as a partner than a policeman,” according to the Times. Lax oversight allowed Emergent to blow through deadlines while still accepting big checks.
Nevertheless, the Trump administration closed a $628 million contract negotiation with Emergent in 2020 to manufacture Covid-19 vaccines developed by Johnson & Johnson (J&J) and AstraZeneca. Officials felt they had little choice: Emergent was one of the few U.S.-based companies capable of producing the desperately needed vaccines.